

Urotensin II Receptor (UT) Antagonist for C. V. Application

Technology Overview

- UT is a new and validated target to treat heart failure and pulmonary arterial hypertension
- Competitive drug candidate for various C. V. application
- Outstanding *in vitro* & *in vivo* efficacy
- Excellent druggability (DMPK, safety & toxicity profile)

Core Technologies

- Two leading compounds(KR-36676 & KR-36996) and series of derivatives;
- Shows strong UT affinity & *in vitro/in vivo* efficacy;
- Excellent response in heart failure, cardiac hypertrophy, myocardial infarction and pulmonary hypertension animal model


Application Area and Advantages

- Acute heart failure
- Pulmonary hypertension
- Asthma and other UT related indications


Accomplishments

- Strong IP Portfolios
- Looking for licensing & collaborative research opportunities


III. Experimental Highlight



III. Experimental Highlight



III. Experimental Highlight



III. Experimental Highlight

